<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rapidly evolving techniques for analysis of the genome provide new opportunities for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>For diffuse <z:hpo ids='HP_0009733'>gliomas</z:hpo> this has resulted in molecular markers with potential for personalized therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Some drugs that utilize pharmacogenomics are currently being tested in clinical trials </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:hpo ids='HP_0002861'>melanoma</z:hpo>, lung-, breast-, gastric- and colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> several molecular markers are already being clinically implemented for diagnosis and treatment </plain></SENT>
<SENT sid="4" pm="."><plain>These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse <z:hpo ids='HP_0009733'>gliomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Better molecular characterization of diffuse <z:hpo ids='HP_0009733'>gliomas</z:hpo>, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed </plain></SENT>
<SENT sid="6" pm="."><plain>We foresee exciting developments in the upcoming years with clinical benefit for the patients </plain></SENT>
</text></document>